Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BIO Notebook: Policy Uncertainty Constraining Dealmaking

19 Jun 2025

• By Mandy Jackson and Joseph Haas

BIO 2025 Notebook Day 4

Related Content

First Quarter M&A Activity Rose On The Strength Of Three Deals

10 Apr 2025

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

30 May 2025

‘Clean Sweep’ Of US CDC Vaccine Committee Puts Kennedy In Driver’s Seat

10 Jun 2025

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

30 May 2025

Novartis Welcomes Abelacimab Back Into The Fold With Anthos Acquisition

11 Feb 2025

BIO Notebook: IPO Window Stays Shut, PRVs Need To Be A Priority, And Focusing On Gene Therapy Safety

17 Jun 2025

AI-Fueled Generate Maps Out Path To Clinic Over Next 24 Months

14 Sep 2023

Amgen Joins AI/ML Gold Rush With Generate Deal

07 Jan 2022

Generate Snares Novartis As Partner/Investor For Its AI/ML Approach

24 Sep 2024

Tezspire Phase III Nasal Polyp Data May Lead To Second Indication

08 Nov 2024

Related Companies

Novartis AG

Anthos Therapeutics Inc.

Amgen, Inc.

Additional Topics

More from BIO

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.